Targeted drug delivery to central nervous system (CNS) for the treatment of neurodegenerative disorders: trends and advances

Central Nervous System Agents in Medicinal Chemistry

Volumn 14, Issue 1, 2014, Pages 43-59

  Goyal, Kritika ^a,b   Koul, Veena ^b   Singh, Yashveer ^c   Anand, Akshay ^a  

^a POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

^b INDIAN INSTITUTE OF TECHNOLOGY DELHI   (India)

^c INDIAN INSTITUTE OF TECHNOLOGY ROPAR   (India)

Author keywords

Blood brain barrier (BBB); CNS drug delivery; Drug transport; Targeting

Indexed keywords

BIOMATERIAL; CARBOPLATIN; GLYCYRRHETINIC ACID PHOSPHOLIPID COMPLEX; LIPOSOME; NANOCAPSULE; NANOSPHERE; PALIPERIDONE; POLYSORBATE 80; SOLID LIPID NANOPARTICLE; DRUG; NANOPARTICLE;

ACTIVE TRANSPORT; ALZHEIMER DISEASE; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; DEGENERATIVE DISEASE; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG IMPLANT; ENDOCYTOSIS; GEL; MICROEMULSION; NANOENCAPSULATION; NERVOUS SYSTEM INFLAMMATION; NEUROTOXICITY; PARTICLE SIZE; TRANSCYTOSIS; ANIMAL; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG EFFECTS; HUMAN; METABOLISM; NEURODEGENERATIVE DISEASES; TREATMENT OUTCOME; TRENDS;

ANIMALS; BLOOD-BRAIN BARRIER; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM DISEASES; DRUG DELIVERY SYSTEMS; HUMANS; NANOPARTICLES; NEURODEGENERATIVE DISEASES; PHARMACEUTICAL PREPARATIONS; TREATMENT OUTCOME;

EID: 84919717862     PISSN: 18715249     EISSN: 18756166     Source Type: Journal    
DOI: 10.2174/1871524914666141030145948     Document Type: Article

References (178)

1. Nolte, J.; The human brain. 1993, Mosby-Year Book Inc. St. Louis.
2. Weller, R.; Christodoulides, M. Anatomy of the meninges: Structural and functional aspects. Meningitis: Cell. Mole. Basis, 2013, 17-30.
3. Sakka, L.; Coll, G. Chazal, J. Anatomy and physiology of cerebrospinal fluid. European Annals Otorhinolaryngology, Head Neck Diseases, 2011, 128(6), 309-316.
4. Decimo, I.; Fumagalli, G.; Berton, V.; Krampera, M.; Bifari, F. Meninges: From protective membrane to stem cell niche. American J. Stem Cells, 2012, 1(2), 92.
5. Glass, C. K.; Saijo, K.; Winner, B.; Marchetto, M. C. Gage, F. H. Mechanisms underlying inflammation in neurodegeneration. Cell, 2010, 140(6), 918-934.
6. Becker, K. J.; Hallenbeck, J. Tolerization to brain and vascular antigens: Targeting autoimmunity after acute brain injuries and preventing stroke, in Immunological mechanisms and therapies in brain injuries and stroke. 2014, Springer. pp. 287-299.
7. Fuller, J. P.; Stavenhagen, J. B.; Teeling, J. L. New roles for fc receptors in neurodegeneration-the impact on immunotherapy for alzheimer's disease. Neurodegeneration, 2014, 8(235).
8. van Eersel, J.; Delerue, F.; Ittner, L. M.; Ke, Y. D. Alzheimer's disease and frontotemporal lobar degeneration: Mouse models, in Neurodegenerative diseases. 2014, Springer. p. 111-129.
9. Pardridge, W. M. Why is the global CNS pharmaceutical market so under-penetrated? Drug Discov. Today, 2002, 7(1), 5-7.
10. Ghersi-Egea, J-F.; Sugiyama, Y. Drug transfer in the choroid plexus. Multiplicity and substrate specificities of transporters. Adv. Drug Deliv. Rev., 2004, 56(12), 1693-1694.
11. Organization, W. H. World health statistics 2010, 2010: World Health Organization.
12. Leshan, R.; Milner, T.; Pfaff, D. W. Blood brain barrier, in Neuroscience in the 21st century. 2013, Springer. pp. 1621-1629.
13. Pardridge, W. M. Brain drug targeting: The Future of Brain Drug Development. 2001: Cambridge University Press.
14. Prince, M.; Bryce, R.; Albanese, E.; Wimo, A.; Ribeiro, W. Ferri, C. P. The global prevalence of dementia: A systematic review and metaanalysis. Alzheimer Dem., 2013, 9(1), 63-75. e62.
15. Kanwar, J. R.; Sriramoju, B. K.; anwar, R. K. Neurological disorders and therapeutics targeted to surmount the blood-brain barrier. Int. J. Nanomedicine, 2012, 7(3259).
16. Finch, C.; Day, J. Molecular biology of aging in the nervous system: A synopsis of the levels of mechanisms. Neurodegen. Diseases, 1994, 33-50.
17. Noelker, C.; Hampel, H.; Dodel, R. Blood-based protein biomarkers for diagnosis and classification of neurodegenerative diseases. Mol. Diag. Ther., 2011, 15(2), 83-102.
18. Baratchi, S.; Kanwar, R. K.; Khoshmanesh, K.; Vasu, P.; Ashok, C.; Hittu, M.; Parratt, A.; Krishnakumar, S.; Sun, X.; Sahoo, S. K. Promises of nanotechnology for drug delivery to brain in neurodegenerative diseases. Cur. Nano., 2009, 5(1), 15-25.
19. Li, J.; Li, T.; Zhang, X.; Tang, Y.; Yang, J.; Le, W. Human superoxide dismutase 1 overexpression in motor neurons of caenorhabditis elegans causes axon guidance defect and neurodegeneration. Neurobiol. Aging, 2014, 35(4), 837-846.
20. Brenner, S. The genetics of caenorhabditis elegans. Genetics, 1974, 77(1), 71-94.
21. O'Brien, C. E.; Wyss-Coray, T. Sorting through the roles of beclin 1 in microglia and neurodegeneration. J. Neur. Pharmacol., 2014, 9(3), 285-292.
22. Mendez-Huergo, S. P.; Maller, S. M.; Farez, M. F.; Mariño, K.; Correale, J.; Rabinovich, G. A. Integration of lectin-glycan recognition systems and immune cell networks in CNS inflammation. Cyt. Growth Factor Rev., 2014.
23. Chen, Y.; Liu, L. Modern methods for delivery of drugs across the blood-brain barrier. Ad. Drug Del. Rev., 2012, 64(7), 640-665.
24. Abbott, N. J.; Patabendige, A. A.; Dolman, D. E.; Yusof, S. R.; Begley, D. J. Structure and function of the blood-brain barrier. Neurobiol. Disease, 2010, 37(1), 13-25.
25. Hartz, A. M. S. Regulation of p-glycoprotein at the blood-brain barrier 2005, The Faculty of Bio Sciences Institute of Pharmacy and Molecular Biotechnology.
26. Bhaskar, S.; Tian, F.; Stoeger, T.; Kreyling, W.; de la Fuente, J. M.; Grazú, V.; Borm, P.; Estrada, G.; Ntziachristos, V.; Razansky, D. Multifunctional nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: Perspectives on tracking and neuroimaging. Part. Fibre Toxicol., 2010, 7(3), 3.
27. Ebnet, K.; Brinkmann, B. F.; Kummer, D.; Misselwitz, S.; Peddibhotla, S. S.; Tuncay, H. Tight junctions, junctional adhesion molecules (jams), and the blood brain barrier, in Tight junctions in cancer metastasis. 2013, Springer. pp. 119-129.
28. Günzel, D.; Alan, S. Claudins and the modulation of tight junction permeability. Physiolog. Rev., 2013, 93(2), 525-569.
29. Cummins, P. M. Occludin: One protein, many forms. Mole. Cell. Biol., 2012, 32(2), 242-250.
30. Engelhardt, B. Development of the blood-brain interface. Blood-Brain Barriers: From Ontogeny to Artificial Interfaces, Volume 1, 2006, 9-39.
31. Jiao, H.; Wang, Z.; Liu, Y.; Wang, P.; Xue, Y. Specific role of tight junction proteins claudin-5, occludin, and zo-1 of the blood-brain barrier in a focal cerebral ischemic insult. J. Mole. Neurosci., 2011, 44(2), 130-139.
32. Weiss, N.; Miller, F.; Cazaubon, S.; Couraud, P-O. The blood-brain barrier in brain homeostasis and neurological diseases. Biochimica et Biophysica Acta (BBA)-Biomembra., 2009, 1788(4), 842-857.
33. Bradbury, M.; Begley, D.; Kreuter, J. The blood-brain barrier and drug delivery to the CNS. 2000: Informa Health Care.
34. Brown, P.; Davies, S.; Speake, T.; Millar, I. Molecular mechanisms of cerebrospinal fluid production. Neuroscience, 2004, 129(4), 955-968.
35. Abbott, N. J.; Rönnbäck, L.; Hansson, E. Astrocyte-endothelial interactions at the blood-brain barrier. Nature Rev. Neurosci., 2006, 7(1), 41-53.
36. Alam, M. I.; Beg, S.; Samad, A.; Baboota, S.; Kohli, K.; Ali, J.; Ahuja, A.; Akbar, M. Strategy for effective brain drug delivery. Eur. J. Pharmaceut. Sci., 2010, 40(5), 385-403.
37. Li, J.; Feng, L.; Fan, L.; Zha, Y.; Guo, L.; Zhang, Q.; Chen, J.; Pang, Z.; Wang, Y.; Jiang, X. Targeting the brain with peg-plga nanoparticles modified with phage-displayed peptides. Biomaterials, 2011, 32(21), 4943-4950.
38. Gan, C. W.; Feng, S-S. Transferrin-conjugated nanoparticles of poly (lactide)-d-α-tocopheryl polyethylene glycol succinate diblock copolymer for targeted drug delivery across the blood-brain barrier. Biomaterials, 2010, 31(30), 7748-7757.
39. Wang, Z. H.; Wang, Z. Y.; Sun, C. S.; Wang, C. Y.; Jiang, T. Y.; Wang, S. L. Trimethylated chitosan-conjugated plga nanoparticles for the delivery of drugs to the brain. Biomaterials, 2010, 31(5), 908-915.
40. Carroll, R. T.; Bhatia, D.; Geldenhuys, W.; Bhatia, R.; Miladore, N.; Bishayee, A.; Sutariya, V. Brain-targeted delivery of tempolloaded nanoparticles for neurological disorders. J. Drug Targeting, 2010, 18(9), 665-674.
41. Chacko, A-M.; Li, C.; Pryma, D. A.; Brem, S.; Coukos, G.; Muzykantov, V. Targeted delivery of antibody-based therapeutic and imaging agents to cns tumors: Crossing the blood-brain barrier divide. Exp. opin. Drug Deliv., 2013, 10(7), 907-926.
42. Doolittle, N. D.; Dósa, E.; Fu, R.; Muldoon, L. L.; Maron, L. M.; Lubow, M. A.; Tyson, R. M.; Lacy, C. A.; Kraemer, D. F.; Butler, R. W. Preservation of cognitive function in primary cns lymphoma survivors a median of 12 years after enhanced chemotherapy delivery. J. Clinical Oncol., 2013, 31(31), 4026-4027.
43. Byun, J. S.; Kwak, B. K.; Kim, J. K.; Jung, J.; Ha, B. C.; Park, S. Engraftment of human mesenchymal stem cells in a rat photothrombotic cerebral infarction model: Comparison of intraarterial and intravenous infusion using mri and histological analysis. J. Korean Neurosurg. Soci., 2013, 54(6), 467-476.
44. Arnberg, F.; Samén, E.; Lundberg, J.; Lu, L.; Grafström, J.; Söderman, M.; Stone-Elander, S.; Holmin, S. Selective intraarterial administration of 18f-fdg to the rat brain-effects on hemispheric uptake. Neuroradiol., 2014, 56(5), 375-380.
45. Patel, M. R.; Patel, R. B.; Bhatt, K. K.; Patel, B. G.; Gaikwad, R. V. Paliperidone microemulsion for nose-to-brain targeted drug delivery system: Pharmacodynamic and pharmacokinetic evaluation. Drug Deliv., 2014, (0), 1-9.
46. Musumeci, T.; Pellitteri, R.; Spatuzza, M.; Puglisi, G. Nose-to-brain delivery: Evaluation of polymeric nanoparticles on olfactory ensheathing cells uptake. J. Pharmaceut. Sci., 2014, 103(2), 628-635.
47. Xu, J.; Xiang, Q.; Su, J.; Yang, P.; Zhang, Q.; Su, Z.; Xiao, F.; Huang, Y. Evaluation of the safety and brain-related tissues distribution characteristics of tat-hafgf via intranasal administration. Biolog. Pharmaceut. Bull., 2014, 37(7), 1149-1157.
48. Tokuda, T.; Noda, T.; Sasagawa, K.; Ohta, J. Optoelectronics devices for biomedical applications. In Conference on Lasers and Electro-Optics/Pacific Rim. 2013. Optical Society of America.
49. MacKay, J. A.; Deen, D. F.; Szoka Jr, F. C. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res., 2005, 1035(2), 139-153.
50. Storm, P. B.; Clatterbuck, R. E.; Liu, Y. J.; Johnson, R. M.; Gillis, E. M.; Guarnieri, M.; Carson Sr, B. S. A surgical technique for safely placing a drug delivery catheter into the pons of primates: Preliminary results of carboplatin infusion. Neurosurgery, 2003, 52(5), 1169-1177.
51. Bernal, G. M.; LaRiviere, M. J.; Mansour, N.; Pytel, P.; Cahill, K. E.; Voce, D. J.; Kang, S.; Spretz, R.; Welp, U.; Noriega, S. E. Convection-enhanced delivery and in vivo imaging of polymeric nanoparticles for the treatment of malignant glioma. Nanomedicine: Nanotech., Biol. Med., 2014, 10(1), 149-157.
52. Saluja, V.; Chopra, D.; Singh, N.; Sekhon, B. Anti-inflammatory potential of dapsone loaded chitosan nanoparticles in streptozotocininduced experimental dementia. IJPSN, 2011, 4(1347-1358).
53. Barth, M.; Pena, P.; Seiz, M.; Thomé, C.; Muench, E.; Weidauer, S.; Hattingen, E.; Kasuya, H.; Schmiedek, P. Feasibility of intraventricular nicardipine prolonged release implants in patients following aneurysmal subarachnoid haemorrhage. British J. Neurosur., 2011, 25(6), 677-683.
54. Sher, F.; Amor, S.; Gerritsen, W.; Baker, D.; Jackson, S. L.; Boddeke, E.; Copray, S. Intraventricularly injected olig2-nscs attenuate established relapsing-remitting eae in mice. Cell Transplantat., 2012, 21(9), 1883-1897.
55. Stroobants, S.; Gerlach, D.; Matthes, F.; Hartmann, D.; Fogh, J.; Gieselmann, V.; D'Hooge, R.; Matzner, U. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Human Mole. Gene, 2011, 20(14), 2760-2769.
56. Wong, H. L.; Wu, X. Y.; Bendayan, R. Nanotechnological advances for the delivery of cns therapeutics. Advanc. Drug Deliv. Rev., 2012, 64(7), 686-700.
57. Ohno, K.; Pettigrew, K.; Rapoport, S. Lower limits of cerebrovascular permeability to nonelectrolytes in the conscious rat. Am. J. Physiol., 1978, 235(3), H299-H307.
58. Neuwelt, E.; Howieson, J.; Frenkel, E.; Specht, D. H.; Weigel, R.; Buchan, C. G.; Hill, S. Therapeutic efficacy of multiagent chemotherapy with drug delivery enhancement by blood-brain barrier modification in glioblastoma. Neurosurgy, 1986, 19(4), 573-582.
59. Pardridge, W. M. Receptor-mediated peptide transport through the blood-brain barrier. Endocrine Rev., 1986, 7(3), 314-330.
60. Pardridge, W. M. Chimeric peptides for neuropeptide delivery through the blood-brain barrier. 1989, Google Patents.
61. Greig, N. H. Drug delivery to the brain by blood-brain barrier circumvention and drug modification, in Implications of the bloodbrain barrier and its manipulation. 1989, Springer. pp. 311-367.
62. Kumagai, A.; Eisenberg, J. B.; Pardridge, W. Absorptive-mediated endocytosis of cationized albumin and a beta-endorphin-cationized albumin chimeric peptide by isolated brain capillaries. Model system of blood-brain barrier transport. J. Biolog. Chem., 1987, 262(31), 15214-15219.
63. Friden, P. M.; Walus, L. R.; Musso, G. F.; Taylor, M. A.; Malfroy, B.; Starzyk, R. M. Anti-transferrin receptor antibody and antibodydrug conjugates cross the blood-brain barrier. Pro. Nat. Acad. Sci., 1991, 88(11), 4771-4775.
64. Friden, P. M.; Walus, L. R.; Watson, P.; Kozarich, J.; Backman, C.; Bergman, H.; Hoffer, B.; Bloom, F.; Granholm, A. Blood-brain barrier penetration and in vivo activity of an ngf conjugate. Science, 1993, 259(5093), 373-377.
65. Alyautdin, R. N.; Petrov, V. E.; Langer, K.; Berthold, A.; Kharkevich, D. A.; Kreuter, J. Delivery of loperamide across the blood-brain barrier with polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Pharma. Res., 1997, 14(3), 325-328.
66. Kreuter, J.; Alyautdin, R. N.; Kharkevich, D. A.; Ivanov, A. A. Passage of peptides through the blood-brain barrier with colloidal polymer particles (nanoparticles). Brain Res., 1995, 674(1), 171-174.
67. Schröder, U.; Sabel, B. A. Nanoparticles, a drug carrier system to pass the blood-brain barrier, permit central analgesic effects of iv dalargin injections. Brain Res., 1996, 710(1), 121-124.
68. Schinkel, A.; Smit, J.; Van Tellingen, O.; Beijnen, J.; Wagenaar, E.; Van Deemter, L.; Mol, C.; Van der Valk, M.; Robanus-Maandag, E.; Te Riele, H. Disruption of the mouse mdr1a pglycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell, 1994, 77(4), 491-502.
69. Batrakova, E. V.; Miller, D. W.; Li, S.; Alakhov, V. Y.; Kabanov, A. V.; Elmquist, W. F. Pluronic p85 enhances the delivery of digoxin to the brain: In vitro and in vivo studies. J. Pharmacol. Experimen. Therapeutics, 2001, 296(2), 551-557.
70. Gerson, T.; Makarov, E.; Senanayake, T. H.; Gorantla, S.; Poluektova, L. Y.; Vinogradov, S. V. Nano-nrtis demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain. Nanomedicine: Nanotechnol. Biol. Medi., 2014, 10(1), 177-185.
71. Huang, R.; Ke, W.; Han, L.; Liu, Y.; Shao, K.; Jiang, C.; Pei, Y. Lactoferrin-modified nanoparticles could mediate efficient gene delivery to the brain in vivo. Brain Res. Bull., 2010, 81(6), 600-604.
72. Orive, G.; Anitua, E.; Pedraz, J. L.; Emerich, D. F. Biomaterials for promoting brain protection, repair and regeneration. Nature Rev. Neurosci., 2009, 10(9), 682-692.
73. Yan, Q.; Yin, Y.; Li, B. Use new plgl-rgd-ngf nerve conduits for promoting peripheral nerve regeneration. Biomed. Eng. Online, 2012, 11(36).
74. Wilson, B.; Samanta, M. K.; Santhi, K.; Kumar, K. P. S.; Paramakrishnan, N.; Suresh, B. Poly (n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat alzheimer's disease. Brain Res., 2008, 1200(159-168).
75. Wilson, B.; Samanta, M. K.; Santhi, K.; Kumar, K. P. S.; Paramakrishnan, N.; Suresh, B. Targeted delivery of tacrine into the brain with polysorbate 80-coated poly (n-butylcyanoacrylate) nanoparticles. Euro. J. Pharma. Biopharma., 2008, 70(1), 75-84.
76. Kurakhmaeva, K. B.; Djindjikhashvili, I. A.; Petrov, V. E.; Balabanyan, V. U.; Voronina, T. A.; Trofimov, S. S.; Kreuter, J.; Gelperina, S.; Begley, D.; Alyautdin, R. N. Brain targeting of nerve growth factor using poly (butyl cyanoacrylate) nanoparticles. J. Drug Targeting, 2009, 17(8), 564-574.
77. Sirsi, S. R.; Williams, J. H.; Lutz, G. J. Poly (ethylene imine)-poly (ethylene glycol) copolymers facilitate efficient delivery of antisense oligonucleotides to nuclei of mature muscle cells of mdx mice. Human Gene. Therapy, 2005, 16(11), 1307-1317.
78. Falzarano, M. S.; Passarelli, C.; Ferlini, A. Nanoparticle delivery of antisense oligonucleotides and their application in the exon skipping strategy for duchenne muscular dystrophy. Nucleic. Acid Therap., 2014, 24(1), 87-100.
79. Imaoka, T.; Date, I.; Ohmoto, T.; Nagatsu, T. Significant behavioral recovery in Parkinson's disease model by direct intracerebral gene transfer using continuous injection of a plasmid DNA-liposome complex. Human Gene Ther., 1998, 9(7), 1093-1102.
80. Spuch, C.; Navarro, C. Liposomes for targeted delivery of active agents against neurodegenerative diseases (Alzheimer's disease and Parkinson's disease). J. Drug Deliv., 2011, 2011.
81. Bondi, M. L.; Craparo, E. F.; Drago, F.; Giammona, G. Nanostructured lipid carriers containing riluzole and phamaceutical formulations containing said particles. 2007, Google Patents.
82. Priano, L.; Albani, G.; Brioschi, A.; Calderoni, S.; Lopiano, L.; Rizzone, M.; Cavalli, R.; Gasco, M. R.; Scaglione, F.; Fraschini, F. Transdermal apomorphine permeation from microemulsions: A new treatment in Parkinson's disease. Movement Disor., 2004, 19(8), 937-942.
83. Chaiyana, W.; Rades, T.; Okonogi, S. Characterization and in vitro permeation study of microemulsions and liquid crystalline systems containing the anticholinesterase alkaloidal extract from tabernaemontana divaricata. Int. J. Pharmaceut., 2013, 452(1), 201-210.
84. Pouladi, M. A.; Brillaud, E.; Xie, Y.; Conforti, P.; Graham, R. K.; Ehrnhoefer, D. E.; Franciosi, S.; Zhang, W.; Poucheret, P.; Compte, E. Np03, a novel low-dose lithium formulation, is neuroprotective in the yac128 mouse model of huntington disease. Neurobiol. Disease, 2012, 48(3), 282-289.
85. Supersaxo, A.; Weder, M.; Weder, H. G. Coenzyme q10 containing microemulsion preconcentrates and microemulsions. 2002, Google Patents.
86. Bondì, M. L.; Craparo, E. F.; Giammona, G.; Drago, F. Brain-targeted solid lipid nanoparticles containing riluzole: Preparation, characterization and biodistribution. Nanomedicine, 2010, 5(1), 25-32.
87. Gupta, Y.; Jain, A.; Jain, S. K. Transferrin-conjugated solid lipid nanoparticles for enhanced delivery of quinine dihydrochloride to the brain. J. Pharmacy Pharmacol., 2007, 59(7), 935-940.
88. Ikeda, K.; Okada, T.; Sawada, S-i.; Akiyoshi, K.; Matsuzaki, K. Inhibition of the formation of amyloid β-protein fibrils using biocompatible nanogels as artificial chaperones. FEBS letters, 2006, 580(28), 6587-6595.
89. Shidhaye, S.; Lotlikar, V.; Malke, S.; Kadam, V. Nanogel engineered polymeric micelles for drug delivery. Curr. Drug Ther., 2008, 3(3), 209-217.
90. Clemens, J. A.; Stephenson, D. T. Implants containing β-amyloid protein are not neurotoxic to young and old rat brain. Neurobiol. Aging, 1992, 13(5), 581-586.
91. Moscicka, A. E.; Czarnecka, K.; Ciach, T. Intellidrug implant for medicine delivery in alzheimer's disease treatment. in Macromolecular Symposia. 2007. Wiley Online Library.
92. Powell, E. M.; Rovena Sobarzo, M.; Mark Saltzman, W. Controlled release of nerve growth factor from a polymeric implant. Brain Res., 1990, 515(1), 309-311.
93. Fung, L. K.; Ewend, M. G.; Sills, A.; Sipos, E. P.; Thompson, R.; Watts, M.; Colvin, O. M.; Brem, H.; Saltzman, W. M. Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res., 1998, 58(4), 672-684.
94. Jain, A.; Betancur, M.; Patel, G. D.; Valmikinathan, C. M.; Mukhatyar, V. J.; Vakharia, A.; Pai, S. B.; Brahma, B.; MacDonald, T. J.; Bellamkonda, R. V. Guiding intracortical brain tumour cells to an extracortical cytotoxic hydrogel using aligned polymeric nanofibres. Nature Materials, 2014, 13(3), 308-316.
95. He, C.; Hu, Y.; Yin, L.; Tang, C.; Yin, C. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles. Biomaterials, 2010, 31(13), 3657-3666.
96. Calvo, P.; Gouritin, B.; Chacun, H.; Desmaële, D.; D'Angelo, J.; Noel, J.-P.; Georgin, D.; Fattal, E.; Andreux, J. P.; Couvreur, P. Long-circulating pegylated polycyanoacrylate nanoparticles as new drug carrier for brain delivery. Pharmaceut. Res., 2001, 18(8), 1157-1166.
97. Koziara, J. M.; Lockman, P. R.; Allen, D. D.; Mumper, R. J. Paclitaxel nanoparticles for the potential treatment of brain tumors. J. Controlled Release, 2004, 99(2), 259-269.
98. Gao, K.; Jiang, X. Influence of particle size on transport of methotrexate across blood brain barrier by polysorbate 80-coated polybutylcyanoacrylate nanoparticles. Int. J. Pharmaceut., 2006, 310(1), 213-219.
99. Nance, E. A.; Woodworth, G. F.; Sailor, K. A.; Shih, T.-Y.; Xu, Q.; Swaminathan, G.; Xiang, D.; Eberhart, C. Hanes, J. A dense poly (ethylene glycol) coating improves penetration of large polymeric nanoparticles within brain tissue. Sci. Translat. Med., 2012, 4(149), 149ra119-149ra119.
100. Costantino, L.; Boraschi, D. Is there a clinical future for polymeric nanoparticles as brain-targeting drug delivery agents? Drug Discov. Today, 2012, 17(7), 367-378.
101. Elsabahy, M.; Wooley, K. L. Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soci. Rev., 2012, 41(7), 2545-2561.
102. Kulkarni, S. A.; Feng, S.-S. Effects of particle size and surface modification on cellular uptake and biodistribution of polymeric nanoparticles for drug delivery. Pharmaceut. Res., 2013, 30(10), 2512-2522.
103. Lai, P.; Daear, W.; Löbenberg, R.; Prenner, E. J. Overview of the preparation of organic polymeric nanoparticles for drug delivery based on gelatine, chitosan, poly (d, l-lactide-co-glycolic acid) and polyalkylcyanoacrylate. Colloids Surfaces B: Biointerfaces, 2014, 118(154-163.
104. Galindo-Rodriguez, S.; Allemann, E.; Fessi, H.; Doelker, E. Physicochemical parameters associated with nanoparticle formation in the salting-out, emulsification-diffusion, and nanoprecipitation methods. Pharmaceutl. Res., 2004, 21(8), 1428-1439.
105. Cheng, J.; Teply, B. A.; Sherifi, I.; Sung, J.; Luther, G.; Gu, F. X.; Levy-Nissenbaum, E.; Radovic-Moreno, A. F.; Langer, R.; Farokhzad, O. C. Formulation of functionalized plga-peg nanoparticles for in vivo targeted drug delivery. Biomaterials, 2007, 28(5), 869-876.
106. Zhang, J.-Y.; Shen, Z.-G.; Zhong, J.; Hu, T.-T.; Chen, J.-F.; Ma, Z.-Q.; Yun, J. Preparation of amorphous cefuroxime axetil nanoparticles by controlled nanoprecipitation method without surfactants. International J. Pharmaceut., 2006, 323(1), 153-160.
107. Geissler, A.; Biesalski, M.; Heinze, T.; Zhang, K. Formation of nanostructured cellulose stearoyl esters via nanoprecipitation. J. Materials Chem. A., 2014, 2(4), 1107-1116.
108. Lale, S. V.; Aravind, A.; Kumar, D. S.; Koul, V. As1411 aptamer and folic acid functionalized ph-responsive atrp fabricated ppegma-pcl-ppegma polymeric nanoparticles for targeted drug delivery in cancer therapy. Biomacromole., 2014, 15(5), 1737-1752.
109. Liu, Y.; Lu, Y.; Luo, G. Modified nanoprecipitation method for polysulfone nanoparticles preparation. Soft Matter, 2014, 10(19), 3414-3420.
110. Phillips, D. J.; Patterson, J. P.; O'Reilly, R. K.; Gibson, M. I. Glutathione-triggered disassembly of isothermally responsive polymer nanoparticles obtained by nanoprecipitation of hydrophilic polymers. Polymer Chem., 2014, 5(1), 126-131.
111. Zhu, H.; Chen, H.; Zeng, X.; Wang, Z.; Zhang, X.; Wu, Y.; Gao, Y.; Zhang, J.; Liu, K. Liu, R. Co-delivery of chemotherapeutic drugs with vitamin e tpgs by porous plga nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials, 2014, 35(7), 2391-2400.
112. Hung, L.-H.; Teh, S.-Y.; Jester, J.; Lee, A. P. Plga micro/nanosphere synthesis by droplet microfluidic solvent evaporation and extraction approaches. Lab. Chip., 2010, 10(14), 1820-1825.
113. Liu, D.; Jiang, S.; Shen, H.; Qin, S.; Liu, J.; Zhang, Q.; Li, R. Xu, Q. Diclofenac sodium-loaded solid lipid nanoparticles prepared by emulsion/solvent evaporation method. J. Nanopart. Res., 2011, 13(6), 2375-2386.
114. Pandav, S.; Naik, J. Non-degradable polymer based microparticles containing water soluble drug prepared by solvent evaporation method. 2013.
115. Roberts, A. D. Zhang, H. Poorly water-soluble drug nanoparticles via solvent evaporation in water-soluble porous polymers. Int. J. Pharmaceu., 2013, 447(1), 241-250.
116. Wang, L.-J.; Yin, Y.-C.; Yin, S.-W.; Yang, X.-Q.; Shi, W.-J.; Tang, C.-H.; Wang, J.-M. Development of novel zein-sodium caseinate nanoparticle (zp)-stabilized emulsion films for improved water barrier properties via emulsion/solvent evaporation. J. Agricul. Food Chem., 2013, 61(46), 11089-11097.
117. Samadi, N.; van Steenbergen, M. J.; van den Dikkenberg, J. B.; Vermonden, T.; van Nostrum, C. F.; Amidi, M.; Hennink, W. E. Nanoparticles based on a hydrophilic polyester with a sheddable peg coating for protein delivery. Pharmaceut. Res., 2014, 1-12.
118. Allouche, J. Synthesis of organic and bioorganic nanoparticles: An overview of the preparation methods, in Nanomaterials: A danger or a promise? 2013, Springer. pp. 27-74.
119. Nagavarma, B.; Hemant, K. Y.; Ayaz, A.; Vasudha, L.; Shivakumar, H. Different techniques for preparation of polymeric nanoparticles-a review. Asian J. Pharmaceut. Clinical Res., 2012, 5(3), 16-23.
120. Konan, Y. N.; Gurny, R.; Allémann, E. Preparation and characterization of sterile and freeze-dried sub-200 nm nanoparticles. Int. J. Pharmaceut., 2002, 233(1), 239-252.
121. Astete, C. E.; Sabliov, C. M. Synthesis and characterization of plga nanoparticles. J. Biomat. Sci. Polymer Edi., 2006, 17(3), 247-289.
122. Rao, J. P.; Geckeler, K. E. Polymer nanoparticles: Preparation techniques and size-control parameters. Prog. Polymer Sci., 2011, 36(7), 887-913.
123. Ali, M. E. Lamprecht, A. Polyethylene glycol as an alternative polymer solvent for nanoparticle preparation. Int. J. Pharmaceut., 2013, 456(1), 135-142.
124. Gupta, P. N.; Jain, S.; Nehate, C.; Alam, N.; Khare, V.; Dubey, R. D.; Saneja, A.; Kour, S.; Singh, S. K. Development and evaluation of paclitaxel loaded plga: Poloxamer blend nanoparticles for cancer chemotherapy. International J. Biolog. Macromol., 2014.
125. Terry, A. B.; Salaam, A. D.; Nyairo, E.; Thomas, V.; Dean, D. R. Plga nanoparticles for the sustained release of rifampicin. J. Nanogeno. Nanomed., 2014, 2(1).
126. Vrignaud, S.; Benoit, J.-P.; Saulnier, P. Strategies for the nanoencapsulation of hydrophilic molecules in polymer-based nanoparticles. Biomaterials, 2011, 32(33), 8593-8604.
127. Zambrano-Zaragoza, M.; Mercado-Silva, E.; Gutiérrez-Cortez, E.; Castaño-Tostado, E.; Quintanar-Guerrero, D. Optimization of nanocapsules preparation by the emulsion-diffusion method for food applications. LWT-Food Science and Technology, 2011, 44(6), 1362-1368.
128. Mozafari, M. Synthesis and characterisation of poly (lactide-coglycolide) nanospheres using vitamin e emulsifier prepared through one-step oil-in-water emulsion and solvent evaporation techniques. 2014.
129. Vauthier, C.; Bouchemal, K. Methods for the preparation and manufacture of polymeric nanoparticles. Pharmaceut. Res., 2009, 26(5), 1025-1058.
130. Jones, M.-C.; Leroux, J.-C. Polymeric micelles-a new generation of colloidal drug carriers. Euro. J. Pharmaceut. Biopharmace., 1999, 48(2), 101-111.
131. Kwon, G. S.; Okano, T. Polymeric micelles as new drug carriers. Adv. Drug Deliv. Rev., 1996, 21(2), 107-116.
132. Nishiyama, N.; Kataoka, K. Current state, achievements, and future prospects of polymeric micelles as nanocarriers for drug and gene delivery. Pharmacol. Ther., 2006, 112(3), 630-648.
133. Bhujbal, S. V.; de Vos, P.; Niclou, S. P. Drug and cell encapsulation: Alternative delivery options for the treatment of malignant brain tumors. Advanced Drug Deliv. Rev., 2014, 67(142-153).
134. Miyata, K.; Christie, R. J.; Kataoka, K. Polymeric micelles for nano-scale drug delivery. Reactive Funct. Polymers, 2011, 71(3), 227-234.
135. Zhang, Y.; Huang, Y.; Li, S. Polymeric micelles: Nanocarriers for cancer-targeted drug delivery. AAPS Pharm. Sci. Tech., 2014, 1-10.
136. Letchford, K.; Burt, H. A review of the formation and classification of amphiphilic block copolymer nanoparticulate structures: Micelles, nanospheres, nanocapsules and polymersomes. Eur. J. Pharma. Biopharmac., 2007, 65(3), 259-269.
137. Chen, Y.; Chen, H.; Zeng, D.; Tian, Y.; Chen, F.; Feng, J.; Shi, J. Core/shell structured hollow mesoporous nanocapsules: A potential platform for simultaneous cell imaging and anticancer drug delivery. ACS Nano, 2010, 4(10), 6001-6013.
138. Mora-Huertas, C.; Fessi, H.; Elaissari, A. Polymer-based nanocapsules for drug delivery. International J. Pharma., 2010, 385(1), 113-142.
139. Felber, A. E.; Dufresne, M.-H.; Leroux, J.-C. Ph-sensitive vesicles, polymeric micelles, and nanospheres prepared with polycarboxylates. Adv. Drug Delivery Rev., 2012, 64(11), 979-992.
140. Xu, F.; Lu, W.; Wu, H.; Fan, L.; Gao, X.; Jiang, X. Brain delivery and systemic effect of cationic albumin conjugated plga nanoparticles. J. Drug Targeting, 2009, 17(6), 423-434.
141. Joana A. Loureiro, B. G.; Manuel A. Coelho, Maria do Carmo Pereira, Sandra Rocha Immunoliposomes for Alzheimer's disease therapy. 2013.
142. Rip, J.; Chen, L.; Hartman, R.; van den Heuvel, A.; Reijerkerk, A.; van Kregten, J.; van der Boom, B.; Appeldoorn, C.; de Boer, M. Maussang, D. Glutathione pegylated liposomes: Pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. J. Drug Targeting, 2014, (0), 1-8.
143. Salvati, E.; Re, F.; Sesana, S.; Cambianica, I.; Sancini, G.; Masserini, M.; Gregori, M. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-β peptide: The chemical design affects the permeability across an in vitro model. International J. Nanomed., 2013, 8(1749).
144. Alyautdin, R.; Khalin, I.; Nafeeza, M. I.; Haron, M. H.; Kuznetsov, D. Nanoscale drug delivery systems and the blood-brain barrier. International J. Nanomed., 2014, 9(795).
145. Xie, Y.; Ye, L.; Zhang, X.; Cui, W.; Lou, J.; Nagai, T.; Hou, X. Transport of nerve growth factor encapsulated into liposomes across the blood-brain barrier: In vitro and in vivo studies. J. Controlled Rel., 2005, 105(1), 106-119.
146. Lu, C.-T.; Zhao, Y.-Z.; Wong, H. L.; Cai, J.; Peng, L.; Tian, X.-Q. Current approaches to enhance cns delivery of drugs across the brain barriers. International J. Nanomed., 2014, 9(2241).
147. Talegaonkar, S.; Azeem, A.; Ahmad, F. J.; Khar, R. K.; Pathan, S. A.; Khan, Z. I. Microemulsions: A novel approach to enhanced drug delivery. Recent Pat. Drug Deliv. Formul., 2008, 2(3), 238-257.
148. Shah, B. M.; Misra, M.; Shishoo, C. J.; Padh, H. Nose to brain microemulsion-based drug delivery system of rivastigmine: Formulation and ex-vivo characterization. Drug Deliv., 2014, (0), 1-13.
149. Patel, R. B.; Patel, M. R.; Bhatt, K. K.; Patel, B. G.; Gaikwad, R. V. Microemulsion-based drug delivery system for transnasal delivery of carbamazepine: Preliminary brain-targeting study. Drug Deliv., 2014, (0), 1-7.
150. Schwuger, M.-J.; Stickdorn, K.; Schomaecker, R. Microemulsions in technical processes. Chem. Rev., 1995, 95(4), 849-864.
151. Kumar, M.; Kakkar, V.; Mishra, A. K.; Chuttani, K.; Kaur, I. P. Intranasal delivery of streptomycin sulfate (strs) loaded solid lipid nanoparticles to brain and blood. International J. Pharmaceut., 2014, 461(1), 223-233.
152. Kuo, Y.-C.; Hong, T.-Y. Delivering etoposide to the brain using catanionic solid lipid nanoparticles with surface 5-ht-moduline. International J. Pharmaceut., 2014, 465(1), 132-142.
153. Kuo, Y.-C. Shih-Huang, C.-Y. Solid lipid nanoparticles carrying chemotherapeutic drug across the blood-brain barrier through insulin receptor-mediated pathway. J. Drug Targeting, 2013, 21(8), 730-738.
154. Mehnert, W.; Mäder, K. Solid lipid nanoparticles: Production, characterization and applications. Adv. Drug Deliv. Rev., 2001, 47(2), 165-196.
155. Kabanov, A.; Batrakova, E. New technologies for drug delivery across the blood brain barrier. Curr. Pharm. Design, 2004, 10(12), 1355.
156. Azadi, A.; Hamidi, M.; Rouini, M.-R. Methotrexate-loaded chitosan nanogels as 'trojan horses' for drug delivery to brain: Preparation and in vitro/in vivo characterization. Int. J. Biol. Macromole., 2013, 62(523-530).
157. De Faveri, S.; Maggiolini, E.; Miele, E.; De Angelis, F.; Cesca, F.; Benfenati, F.; Fadiga, L. Bio-inspired hybrid microelectrodes: A hybrid solution to improve long-term performance of chronic intracortical implants. Front. Neuroengineering, 2014, 7.
158. Potter, K. A.; Jorfi, M.; Householder, K. T.; Foster, E. J.; Weder, C. Capadona, J. R. Curcumin-releasing mechanically adaptive intracortical implants improve the proximal neuronal density and blood-brain barrier stability. Acta Biomat., 2014, 10(5), 2209-2222.
159. Harris, J.; Capadona, J.; Miller, R.; Healy, B.; Shanmuganathan, K.; Rowan, S.; Weder, C. Tyler, D. Mechanically adaptive intracortical implants improve the proximity of neuronal cell bodies. J. Neural. Eng., 2011, 8(6), 066011.
160. Sarris, J.; Panossian, A.; Schweitzer, I.; Stough, C. Scholey, A. Herbal medicine for depression, anxiety and insomnia: A review of psychopharmacology and clinical evidence. Eur. Neuropsychopharmacology, 2011, 21(12), 841-860.
161. Bonifácio, B. V.; da Silva, P. B.; dos Santos Ramos, M. A.; Negri, K. M. S.; Bauab, T. M. Chorilli, M. Nanotechnology-based drug delivery systems and herbal medicines: A review. Int. J. Nanomed., 2014, 9(1).
162. Devi, V. K.; Jain, N.; Valli, K. S. Importance of novel drug delivery systems in herbal medicines. Pharmacog. Rev., 2010, 4(7), 27.
163. Bombardelli, E.; Mustich, G. Bilobalide-phospholipid comlex, their uses and formulation containing them. US Patent No. EPO-275005, 1991.
164. Jain, N.; Gupta, B. P.; Thakur, N.; Jain, R.; Banweer, J.; Jain, D. K.; Jain, S. Phytosome: A novel drug delivery system for herbal medicine. Int. J. Pharm. Sci. Drug Res., 2010, 2(4), 224-228.
165. Chakrapany Sharma, C. S. Nano carriers of novel drug delivery system for "ayurveda herbal remedies" need of hour-a bird's eye view. Am. J. Pharmatech. Res., 2014, 4(2), 10.
166. Zhang, Z.; Wang, J.; Lu, J. [optimization of the preparation of 3', 5'-dioctanoyl-5-fluoro-2'-deoxyuridine pharmacosomes using central composite design]. Yao xue xue bao= Acta pharmaceutica. Sinica, 2001, 36(6), 456-461.
167. Mathew, A.; Fukuda, T.; Nagaoka, Y.; Hasumura, T.; Morimoto, H.; Yoshida, Y.; Maekawa, T.; Venugopal, K.; Kumar, D. S. Curcumin loaded-plga nanoparticles conjugated with tet-1 peptide for potential use in alzheimer's disease. PLoS One, 2012, 7(3), e32616.
168. Lees, A.; Olanow, C.; Van Der Giessen, R.; Wagner, H. Pharmaceutical compositions and uses comprising mucuna pruriens seed powder and extracts thereof in the treatment neurological diseases, 2003, Google Patents.
169. Zhong, H.; Deng, Y.; Wang, X.; Yang, B. Multivesicular liposome formulation for the sustained delivery of breviscapine. International J. Pharmaceut., 2005, 301(1), 15-24.
170. Anand, A.; Saraf, M. K.; Prabhakar, S. Antiamnesic effect of b. Monniera on l-nna induced amnesia involves calmodulin. Neurochem. Res., 2010, 35(8), 1172-1181.
171. Saraf, M. K.; Prabhakar, S.; Khanduja, K. L.; Anand, A. Bacopa monniera attenuates scopolamine-induced impairment of spatial memory in mice. Evidence-Based Complemen. Alterna. Med., 2011, 2011.
172. Habbu, P.; Madagundi, S.; Kulkarni, R.; Jadav, S.; Vanakudri, R.; Kulkarni, V. Preparation and evaluation of bacopa-phospholipid complex for antiamnesic activity in rodents. Drug Invention Today, 2013, 5(1), 13-21.
173. Vitthal, K. U.; Pillai, M.; Kininge, P. Study of solid lipid nanoparticles as a carrier for bacoside. Int. J. Pharma. BioSci., 2013.
174. Han, L.; Zhang, A.; Wang, H.; Pu, P.; Kang, C.; Chang, J. Construction of novel brain-targeting gene delivery system by natural magnetic nanoparticles. J. Applied Polymer Sci., 2011, 121(6), 3446-3454.
175. Xin, H.; Jiang, X.; Gu, J.; Sha, X.; Chen, L.; Law, K.; Chen, Y.; Wang, X.; Jiang, Y.; Fang, X. Angiopep-conjugated poly (ethylene glycol)-co-poly (ε-caprolactone) nanoparticles as dual-targeting drug delivery system for brain glioma. Biomaterials, 2011, 32(18), 4293-4305.
176. Vallhov, H.; Qin, J.; Johansson, S. M.; Ahlborg, N.; Muhammed, M. A.; Scheynius, A.; Gabrielsson, S. The importance of an endotoxin-free environment during the production of nanoparticles used in medical applications. Nano. lett., 2006, 6(8), 1682-1686.
177. Boraschi, D.; Lucchesi, D.; Hainzl, S.; Leitner, M.; Maier, E.; Mangelberger, D.; Oostingh, G. J.; Pfaller, T.; Pixner, C.; Posselt, G. Il-37: A new anti-inflammatory cytokine of the il-1 family. Europ. Cytokine Network, 2011, 22(3), 127-147.
178. Shemetov, A. A.; Nabiev, I.; Sukhanova, A. Molecular interaction of proteins and peptides with nanoparticles. ACS Nano., 2012, 6(6), 4585-4602.